Axogen (AXGN) Insider Alan Levine Buys 14,150 Shares

Alan Levine Increases Stake in Axogen

Alan Levine bought 14,150 shares of Axogen, Inc. (AXGN) on June 19, 2026. This purchase is valued at around $630,000 based on the current stock price of $44.69. Levine's transaction adds to a series of insider purchases at the company, highlighting ongoing confidence from those close to Axogen.

Recent Insider Transactions

This isn't the first time Levine has been active in the stock. On June 24, 2026, he bought 4,392 shares of Axogen. Other insiders also made purchases on the same day, including John Johnson, Burke William Mr., Wendell Amy Mcbride, Paul Thomas, and Joseph Tyndall, each acquiring 4,392 shares or more. This collective buying activity suggests a shared optimism among Axogen's leadership.

Axogen Stock Performance

Axogen's stock has shown strong performance recently, trading near its 50-day moving average of $45.28. The shares have a notable history, with a 52-week range between $15.27 and $52.91. This upward trend is significant as it reflects recovery and growth potential in the medical device sector, particularly for technologies aimed at nerve regeneration and repair.

Analysts Set New Price Targets

Analysts are generally optimistic about Axogen, giving it a consensus rating of 'strong buy'. The mean price target sits at $53.90, with several firms, including B of A Securities and Barclays, initiating coverage with positive outlooks. B of A Securities set a target of $52.00 on October 12, 2026, while Barclays set a target of $55.00 on October 7, 2026. This positive sentiment aligns with the company's recent performance and growth trajectory.

What Axogen, Inc. Does

Axogen, Inc. focuses on developing and selling products for peripheral nerve regeneration and repair. Its offerings include the Avance Nerve Graft and Axoguard Nerve Protector, which are essential for surgical procedures. The company's growth in the medical devices industry is reflected in the recent insider activity and analyst ratings.

What's Ahead for Axogen, Inc.

Investors will be watching for Axogen's next earnings report scheduled for October 28, 2026. The recent insider purchases and positive analyst ratings indicate a bullish outlook for the company, although the 13F filings reflect past holdings and may not represent current positions. As the company continues to innovate in nerve repair technologies, further developments in insider trading could provide additional insights into management's confidence.